124 related articles for article (PubMed ID: 37879536)
21. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432.
Wang F; Wei XL; Wang FH; Xu N; Shen L; Dai GH; Yuan XL; Chen Y; Yang SJ; Shi JH; Hu XC; Lin XY; Zhang QY; Feng JF; Ba Y; Liu YP; Li W; Shu YQ; Jiang Y; Li Q; Wang JW; Wu H; Feng H; Yao S; Xu RH
Ann Oncol; 2019 Sep; 30(9):1479-1486. PubMed ID: 31236579
[TBL] [Abstract][Full Text] [Related]
22. Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.
Moreno V; Roda D; Pikiel J; Trigo J; Bosch-Barrera J; Drew Y; Kristeleit R; Hiret S; Bajor DL; Cruz P; Beck JT; Ghosh S; Dabrowski C; Antony G; Duan T; Veneris J; Zografos E; Subramanian J
Clin Lung Cancer; 2022 Nov; 23(7):e415-e427. PubMed ID: 35729005
[TBL] [Abstract][Full Text] [Related]
23. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
Spigel DR; Luft A; Depenbrock H; Ramlau R; Khalil M; Kim JH; Mayo C; Chao GY; Obasaju C; Natale R
Clin Lung Cancer; 2017 Sep; 18(5):480-488. PubMed ID: 28365238
[TBL] [Abstract][Full Text] [Related]
24. Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial.
Lu S; Wang J; Yu Y; Yu X; Hu Y; Ai X; Ma Z; Li X; Zhuang W; Liu Y; Li W; Cui J; Wang D; Liao W; Zhou J; Wang Z; Sun Y; Qiu X; Gao J; Bao Y; Liang L; Wang M
J Thorac Oncol; 2021 Sep; 16(9):1512-1522. PubMed ID: 34033975
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.
Besse B; Garrido P; Cortot AB; Johnson M; Murakami H; Gazzah A; Gil M; Bennouna J
Lung Cancer; 2020 Apr; 142():63-69. PubMed ID: 32114283
[TBL] [Abstract][Full Text] [Related]
26. Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC.
Antonia SJ; Balmanoukian A; Brahmer J; Ou SI; Hellmann MD; Kim SW; Ahn MJ; Kim DW; Gutierrez M; Liu SV; Schöffski P; Jäger D; Jamal R; Jerusalem G; Lutzky J; Nemunaitis J; Calabrò L; Weiss J; Gadgeel S; Bhosle J; Ascierto PA; Rebelatto MC; Narwal R; Liang M; Xiao F; Antal J; Abdullah S; Angra N; Gupta AK; Khleif SN; Segal NH
J Thorac Oncol; 2019 Oct; 14(10):1794-1806. PubMed ID: 31228626
[TBL] [Abstract][Full Text] [Related]
27. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
28. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.
Herbst RS; Baas P; Perez-Gracia JL; Felip E; Kim DW; Han JY; Molina JR; Kim JH; Dubos Arvis C; Ahn MJ; Majem M; Fidler MJ; Surmont V; de Castro G; Garrido M; Shentu Y; Emancipator K; Samkari A; Jensen EH; Lubiniecki GM; Garon EB
Ann Oncol; 2019 Feb; 30(2):281-289. PubMed ID: 30657853
[TBL] [Abstract][Full Text] [Related]
29. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors.
Huang Z; Xu Y; Hong W; Gong L; Chen K; Qin J; Xie F; Wang F; Tian X; Meng X; Feng W; Li L; Zhang B; Kang X; Fan Y
Front Immunol; 2023; 14():1258573. PubMed ID: 37936687
[TBL] [Abstract][Full Text] [Related]
30. Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis.
Li DN; Lu WQ; Yang BW; Zhang LY; Jin B; Wang S; Che XF; Li C; Liu YP; Qu XJ
Front Immunol; 2021; 12():666909. PubMed ID: 34149702
[TBL] [Abstract][Full Text] [Related]
31. SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.
Zhao J; Yu X; Huang D; Ma Z; Gao B; Cui J; Chu Q; Zhou Q; Sun M; Day D; Wu J; Pan H; Wang L; Voskoboynik M; Wang Z; Liu Y; Li H; Zhang J; Peng Y; Wu YL
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36808075
[TBL] [Abstract][Full Text] [Related]
32. AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.
Zhao Y; Chen G; Chen J; Zhuang L; Du Y; Yu Q; Zhuang W; Zhao Y; Zhou M; Zhang W; Zhang Y; Wan Y; Li W; Song W; Wang ZM; Li B; Xia M; Yang Y; Fang W; Huang Y; Zhang L
EClinicalMedicine; 2023 Aug; 62():102106. PubMed ID: 37593227
[TBL] [Abstract][Full Text] [Related]
33. Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study.
Yang JJ; Huang C; Fan Y; Pan H; Feng J; Jiang L; Li XY; Liu XQ; Xiong JP; Zhao YQ; Cheng Y; Ma R; Wang J; Wang Y; Liu YH; Lin DM; Wang T; Shi W; Zou J; Wu YL
Cancer Immunol Immunother; 2022 Jun; 71(6):1393-1402. PubMed ID: 34668977
[TBL] [Abstract][Full Text] [Related]
34. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.
Gao X; Xu N; Li Z; Shen L; Ji K; Zheng Z; Liu D; Lou H; Bai L; Liu T; Li Y; Li Y; Fan Q; Feng M; Zhong H; Huang Y; Lou G; Wang J; Lin X; Chen Y; An R; Li C; Zhou Q; Huang X; Guo Z; Wang S; Li G; Fei J; Zhu L; Zhu H; Li X; Li F; Liao S; Min Q; Tang L; Shan F; Gong J; Gao Y; Zhou J; Lu Z; Li X; Li J; Ren H; Liu X; Yang H; Li W; Song W; Wang ZM; Li B; Xia M; Wu X; Ji J
Lancet Oncol; 2023 Oct; 24(10):1134-1146. PubMed ID: 37797632
[TBL] [Abstract][Full Text] [Related]
35. A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer.
Galffy G; Lugowska I; Poddubskaya EV; Cho BC; Ahn MJ; Han JY; Su WC; Hauke RJ; Dyar SH; Lee DH; Serwatowski P; Estelles DL; Holden VR; Kim YJ; Vladimirov V; Horvath Z; Ghose A; Goldman A; di Pietro A; Wang J; Murphy DA; Alhadab A; Laskov M
ESMO Open; 2023 Jun; 8(3):101173. PubMed ID: 37141847
[TBL] [Abstract][Full Text] [Related]
36. Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer.
Cho BC; Yoh K; Perets R; Nagrial A; Spigel DR; Gutierrez M; Kim DW; Kotasek D; Rasco D; Niu J; Satouchi M; Ahn MJ; Lee DH; Maurice-Dror C; Siddiqi S; Ren Y; Altura RA; Bar J
Lung Cancer; 2021 Sep; 159():162-170. PubMed ID: 34371366
[TBL] [Abstract][Full Text] [Related]
37. JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.
Ramalingam SS; Thara E; Awad MM; Dowlati A; Haque B; Stinchcombe TE; Dy GK; Spigel DR; Lu S; Iyer Singh N; Tang Y; Teslenko I; Iannotti N
Cancer; 2022 Jan; 128(1):65-74. PubMed ID: 34478166
[TBL] [Abstract][Full Text] [Related]
38. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
39. Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.
Gubens MA; Sequist LV; Stevenson JP; Powell SF; Villaruz LC; Gadgeel SM; Langer CJ; Patnaik A; Borghaei H; Jalal SI; Fiore J; Saraf S; Raftopoulos H; Gandhi L
Lung Cancer; 2019 Apr; 130():59-66. PubMed ID: 30885353
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
